Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 38838500

An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
ESMO Open
Publication date
2024 Jun
First author
Vogel A

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Vogel A
      type
      Author
    2. name
      Sahai V
      type
      Author
    3. name
      Hollebecque A
      type
      Author
    4. name
      Vaccaro GM
      type
      Author
    5. name
      Melisi D
      type
      Author
    6. name
      Al Rajabi RM
      type
      Author
    7. name
      Paulson AS
      type
      Author
    8. name
      Borad MJ
      type
      Author
    9. name
      Gallinson D
      type
      Author
    10. name
      Murphy AG
      type
      Author
    11. name
      Oh DY
      type
      Author
    12. name
      Dotan E
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Vogel A
      type
      Author
    2. name
      Sahai V
      type
      Author
    3. name
      Hollebecque A
      type
      Author
    4. name
      Vaccaro GM
      type
      Author
    5. name
      Melisi D
      type
      Author
    6. name
      Al Rajabi RM
      type
      Author
    7. name
      Paulson AS
      type
      Author
    8. name
      Borad MJ
      type
      Author
    9. name
      Gallinson D
      type
      Author
    10. name
      Murphy AG
      type
      Author
    11. name
      Oh DY
      type
      Author
    12. name
      Dotan E
      type
      Author
    bibliography ids
    1. nci-bib-3dbaa84dd8d1405927884d0b
    book metadata
    content sha256
    753f8e3c7eece11578ae98a3f30c41e67206ca639ea2eb5c68fd677891f19ef6
    document type
    citation
    dois
    1. 10.1016/j.esmoop.2024.103488
    electronic publication date
    display
    2024 Jun 4
    precision
    day
    year
    2024
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:38838500
    immutable id
    pubmed:38838500@753f8e3c7eece11578ae98a3f30c41e67206ca639ea2eb5c68fd677891f19ef6
    journal
    abbreviation
    ESMO Open
    issn electronic
    2059-7029
    issn print
    Source null
    issue
    6
    name
    ESMO open
    nlm unique id
    101690685
    pages
    103488
    volume
    9
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      38838500
      provenance
      batch id
      3e43afde6f26fc8df6da
      provider
      NCBI PubMed ESummary
      record sha256
      5e3c4ea1cbef18d5fa01525d3638b999cc567fa28c06bfeb28287d57a2926d74
      response sha256
      fa51c3b310a444d84ada833c4cda53c9e4e97161ab5048020b99c51e56e843d2
      retrieved at
      2026-09-09T23:48:21.145285+00:00
      publication date
      display
      2024 Jun
      precision
      month
      year
      2024
      publication types
      1. Journal Article
      2. Multicenter Study
      3. Clinical Trial, Phase II
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/38838500/
      title
      An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202.

      Preserved source evidence · Not medical advice